English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Fulvestrant is indicated in the treatment of locally advanced or metastatic breast cancer in postmenopausal women with hormone receptor-positive breast cancer as second line at the present time, after first line hormone therapy. We present here a case report of a 47-year-old woman diagnosed with infiltrating ductal carcinoma left breast cancer in 1998, stage II, luminal B HER2-positive and a liver and ganglionar relapse 3 years later. After radical treatment, fulvestrant was indicated. She has been 10 years with this treatment, with an excellent tolerance and without showing progression until now.

Fulvestrant in breast cancer: also a good option in triple-positive breast cancer